Metformin Medreg (Metformin Hydrochloride)

The drug activates AMP‑activated protein kinase (AMPK), which reduces hepatic glucose production and increases insulin‑mediated glucose uptake in muscle and fat cells. This dual action lowers circulating glucose levels without directly stimulating insulin secretion.

The appropriate dose of Metformin Medreg is determined by the prescribing healthcare professional based on the individual’s medical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformin Hydrochloride is classified as Pregnancy Category B, indicating no proven risk in animal studies and limited human data. It may be continued during pregnancy if benefits outweigh risks, and it is excreted in breast milk in small amounts. Consultation with a healthcare provider is essential.

To request Metformin Medreg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformin belongs to the biguanide class and is often first‑line therapy because it does not cause weight gain and has a low risk of hypoglycemia compared with sulfonylureas or insulin. Unlike some newer agents, it is inexpensive and has a well‑established safety profile, though gastrointestinal side effects are more common.

Metformin Medreg should be stored at room temperature, below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metformin Medreg is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or when combined with certain contrast agents. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, or rapid breathing develop.

Metformin Medreg is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or any component of the formulation.